Carcinoid syndrome other imaging findings

Carcinoid syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Carcinoid Syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Carcinoid syndrome other imaging findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Carcinoid syndrome other imaging findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Carcinoid syndrome other imaging findings
CDC on Carcinoid syndrome other imaging findings
Carcinoid syndrome other imaging findings in the news
Blogs on Carcinoid syndrome other imaging findings
Directions to Hospitals Treating Carcinoid syndrome
Risk calculators and risk factors for Carcinoid syndrome other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

Other imaging studies for carcinoid tumor include somatostatin scintigraphy with 111Indium-octreotide, bone scintigraphy with 99mTc-methylene diphosphonate (99mTcMDP), 123 I-metaiodobenzylguanidine (MIBG) scintigraphy, capsule endoscopy (CE), enteroscopy, and angiography.

Other Imaging Findings

Other imaging modalities for gastrointestinal carcinoids include the use of:

• Somatostatin scintigraphy with 111Indium-octreotide
• Bone scintigraphy with 99mTc-methylene diphosphonate (99mTcMDP)
• 123 I-metaiodobenzylguanidine (MIBG) scintigraphy
• Capsule endoscopy (CE)
• Enteroscopy
• Positron emission tomography (PET)
• Angiography

Somatostatin Receptor Scintigraphy

• It is the gold-standard in confirming the location of functioning neuroendocrine tumour tissue.
• There are five different somatostatin receptor (SSTR) subtype, more than 70% of neuroendocrine tumors of both the gastrointestinal tract and pancreas express multiple subtypes predominantly 2 and 5.
• Mid-gut carcinoids predominantly express somatostatin receptors from sub-group 2 (sst2).
• The synthetic radiolabeled SSTR analog 111In-DTP-d-Phe10-{octreotide} affords an important method, somatostatin receptor scintigraphy (SRS), to localize carcinoid tumors, especially sst(2)-positive and sst(5)-positive tumors, imaging is accomplished in one session, and small primary tumors and metastases are diagnosed more readily than with conventional imaging or imaging techniques requiring multiple sessions.
• Overall sensitivity of the octreotide scan is reported to be as high as 90%.

Bone Scintigraphy

• Bone scintigraphy with 99mTcMDP is the primary imaging modality for identifying bone involvement in neuroendocrine tumors and detection rates are reported to be 90% or higher.
• 123I-MIBG is concentrated by carcinoid tumors in as many as 70% of cases using the same mechanism as norepinephrine and is used successfully to visualize carcinoids.
• However, 123I-MIBG appears to be about half as sensitive as 111In-octreotide scintigraphy in detecting tumors.

Endoscopic Ultrasonography (EUS)

Endoscopic ultrasonography (EUS) may be a sensitive method for the detection of gastric and duodenal carcinoids and may be superior to conventional ultrasound, particularly in the detection of small tumors (2 mm–3 mm) that are localized in the bowel lumen. In one study, the EUS was reported to have an accuracy of 90% for the localization and staging of colorectal carcinoids.

Positron Emission Tomography–Computed Tomography

PET-CT is now playing an ever-increasing role in both localizing disseminated cancer and monitoring the disease response to systemic therapies.

• Carcinoid-specific agents includes: 5-hydroxy-l-tryptophan (5-HTP),64Cu-1,4,8,11-tetra-azacyclo-tetradecane-N,N′,N″, N‴-tera-acetic acid (TETA-OC) and 18F-dopa have been used.

Angiography

MRI angiography has replaced angiography to a large extent. However, selective angiography may be useful to:

• Demonstrate the degree of tumor vascularity
• Identify the sources of vascular supply
• Delineate the relationship of the tumor to adjacent major vascular structures
• Provide information regarding vascular invasion